IC18: Management of Osteoporosis Flashcards

1
Q

List at least 4 causes of low bone mass

A
  1. Age
  2. Menopause
  3. Alcohol consumption
  4. Smoking
  5. Physical inactivity
  6. Low serum calcium
  7. Medication use
  8. Secondary due to other disease (eg. drugs, endocrine disorder, GI disease, nutritional disorer, marrow related disorders, organ transplantation)

Menopause: no estrogen, which plays a role in maintaining bone density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

State 3 secondary causes of osteoporosis

A
  1. Drugs: glucocorticoids, immunosuppresants, Antiseizures (esp phenobarbital & phenytoin), aromatase inhibitors, GnRH agonists & antagonists, heparin, cancer chemotherapy
  2. Endocrine disorders
  3. GI disease/nutritional disorders
  4. Marrow related disorders
  5. Organ transplantation eg. bone marrow, heart, kidney

Drugs esp glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why do patients with RA have an increased risk of osteoporosis?

A

RA patients might be on long term glucocorticoids which predisposes risk for osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

State the signs & symptoms of osteoporosis

A
  1. Asymptomatic (no pain), until patient presents with
  2. Fragility fracture of spine, hip, wrist, humerus, pelvis (occurs with low trauma)
    - hip: height loss & kyphosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does a fragility fracture differ from normal fractures?

A

Fragility: occur due to minimal trauma or no identifiable trauma eg. fall from standing height
Normal: Result from significant trauma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

State the group(s) that should be assessed for osteoporosis & fracture risk

A
  1. Post menopausal women
  2. Men >= 65yo
  3. 1 or 2, with risk factors eg. Family hx of OP/fragility fracture, previous fragility fracture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

State the risk factors for osteoporosis or fragility fractures

A
  1. FHx of osteoporosis or fragility fracture
  2. Previous fragility #
  3. Ageing
  4. Low body weight
  5. Height loss > 2cm w/in 3 years
  6. Early menopause <= 45
  7. Presence of disease that can lower bone density or increase fracture risk
  8. Certain medications eg. glucocorticoids
  9. Low Ca intake (< 500mg/d)
  10. Excessive alcohol intake (> 2 units/d)
  11. Smoking (any)
  12. prolonged immobility
  13. Hx of falls
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

State a tool used to detect osteoporosis risk in post-menopausal women

A

Osteoporosis Self-Assessment Tool for Asians (OSTA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

State the OSTA score breakdowns and the recommendations

A
  • High risk (>20): Consider DXA scan. Chance of finding osteoporosis (low bmd) is high in this group
  • Medium risk (0-20): Consider DXA scan if any other risk factor (eg. Fhx etc)
  • Low risk (< 0): Consider deferring DXA

Medium/high risk refer to polyclinic for further testing to decide if osteoporosis tx is needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is osteoporosis diagnosed?

A
  1. Hx of fragility # at vertebral, hip, wrist, humerus, rib or pelvis
    * Occurs spontaneously from minor trauma that would not ordinarily result in # (eg. fall from standing height or less)
    * Asymptomatic vertebral # can be visually identified as > 20% dec in vetebral height
  2. BMD measurement via DXA hip &/or spine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

State the DXA T-score SD breakdowns & their definitions

A
  • T-score ≤ 2.5 SD - osteoporosis
  • T-score -1 to 2.5 SD - osteopenia
  • T-score ≥ 1SD - normal bone density
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In DXA scores,

T-score comapres BMD against ____, while Z-score compares BMD against _____

A

T-score: against young adult popn
Z-score: against patient’s age & sex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A Z-score of ≤ 2 suggests?

A

Coexisting problems that can contribute to osteoporosis (eg. glucocorticoid therapy, alcoholism)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

State 4 commonly indicated laboratory tests & their rationale to identify secondary contributors of osteoporosis

A
  1. Creatinine - determine baseline renal fxn & indicate CKD-MBD
  2. Full blood count - malignancies, malabsorption, others
  3. Corrected Calcium
  4. 25-hydroxyvitaminD
    Others
  5. TSH
  6. Erythrocyte sedimentation rate - indicate rheumatological diseae
  7. Alkaline phosphatase - incr lvl might indiciate liver disease, paget’s disease
  8. Serum phosphate
  9. Spot urine calcium
  10. Serum total testosterone - decr lvl might indiciate reduce hypogandism

  1. Corrected Calcium
    - incr Ca: primary hyperparathyroidism or malignancy.
    - Decr Ca: malabsorption or vit D deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is FRAX and what is it used for?

A

FRAX, Fracture Risk Assessment Tool, is a tool to determine absolute fracture risk and assist in treatment decisions.
FRAX indicates the 10 year probability of developing a fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Under FRAX, when should osteoporosis treatment be started?

A

Treatment should be considered if 10-year probability is high for
* 1) Major osteoporotic fracture or
* 2) Hip fracture

To note FRAX uses US cut off, no SG studies yet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

State the treatment criteria(s) for osteoporosis

A
  1. Patients presenting with fragility #
  2. Patients without fragility #, but DXA BMD T-score of ≤ 2.5
  3. Osteopenic (T score > -2.5 but < 1), without a fragility #, but with high # risk (eg. FRAX > 3 %, or ≥ 20% major osteoporotic #)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the first-line treatment of osteoporosis?

A

Oral bisphosphonates (alendronate, risidronate, ibandronate)

Zoledronate is IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

State the pharmacological treatments used to treat osteoporosis

A
  1. Bisphosphonates (PO/IV)
  2. RANKL inhibitor: Denosumab
  3. Sclerostin inhibitor: Romosuzumab
  4. Recombinant parathyroid hormone: Teriparatide
  5. SERM: Raloxifene
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

State the dosing and frequency of administration of IV Zoledronic acid

A

5mg q year, as 30min infusion (ensure adequate hydration before infusion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

State the dosing & administration of 1) PO Alendronate
2) PO Risedronate &
3) PO Ibandroante

A

1) 70mg q week
2) 35mg q week
3) 150mg q month

ibandronate no subsidy & need to fast >6H before taking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

List the contraindication(s) of Zoledronic acid

A
  1. CrCl < 35ml/min
  2. Hypocalcemia
23
Q

List the contraindiaction(s) of PO bisphosphonates (alendronate, risedronate, ibandronate)

A
  1. CrCl < 30ml/min
  2. Hypocalcemia
  3. Oesophageal or gastric abnormalities (eg. gastric ulcer, achalsia, uncontrolled GERD, erosive esophagitis)
  4. Inability to stand/sit upright ≥ 30min
  5. Aspiration risk (eg. difficulty swallowing liquid)
24
Q

State 2 rare but serious side effects of using IV and PO bisphosphonates

A
  1. Osteonecrosis of the jaw
  2. Atypical femoral # (monitor for thign/hip/groin pain while on tx)
25
State 2 conditions leading to an increase risk of ONJ when using bisphosphonates
1. Using zoledronic acid 2. Cancer patients
26
Describe the treatment duration for bisphosphonates (IV & PO) for **low # risk patients**
* PO: 5 years * IV: 3 years * Restart after 2 years if BMD decrease > 4-5% or tx criteria is met again
27
Describe the treatment duration for bisphosphonates (IV & PO) for **high # risk patients**
* PO: 10 years * IV: 6 years
28
State the dosing and frequency of administration of SC Denosumab
1 injection once q 6mth
29
State the contraindication(s) of denosumab
Hypocalcemia
30
What is a serious side effect to monitor while using denosumab?
Increased risk of infections eg. diverticulitis, pneumonia, appendicitis, cellulitis
31
What is the treatment duration for denosumab?
Indefinite duration
32
Why should patients not miss their denosumab dose?
Missed doses can increase the risk of vertebral fractures
33
State the dosing and frequency of administration for SC Teriparatide
Once q6mth
34
List the contraindications of teriparatide
1. CrCl < 30 2. Paget's disease/Hx of bone radiation 3. Hypercalcemia
35
List a side effect of teriparatide
Postural hypotension
36
What is the treatment duration of teriparatide?
< 2 years
37
State the dosing and frequency of administration for PO raloxifene
60mg OD
38
State the contraindication(s) of PO raloxifene
* CrCl < 30 * Hx current VTE * Hepatic & severe renal impairment
39
State the side effect(s) of PO raloxifene
Increase VTE & Stroke risk
40
When should PO raloxifene be used in woman?
For woman with no hot flushes
41
State the frequency of administration for Romosozumab ## Footnote Sclerostin inhibitor
Once a month
42
State the contraindications of romosuzumab
Hx of CVS event/stroke (Romosozumab incr risk of MI, stroke, CVS & death)
43
What is the treatment duration for romosozumab?
1 year
44
List the risk factors for ONJ
1. Tooth extraction or other invasive dental procedures 2. Hx of cancer, radiotherapy 3. Poor oral hygiene 4. Concomitant therapy eg. angiogensis inhibitors, bisphosphonates, chemotherapy, corticosteroids, denosumab 5. Cormobid disorders eeg. anemia, coagulopathy, infxn, preexisting dental or periodontal disease
45
List the counselling points to reduce the risk of ONJ in patients
1. Smoking cessation 2. Avoid invasive dental procedures during bisphosphonate tx 3. Maintain good oral hygiene
46
How should patients who developed ONJ while on bisphosphonate therapy be managed?
* Seek dental care by oral surgeon/dentist * Consider Tx discontinuation based on risk vs benefits
47
Where do atypical femoral fractures usually present?
Hip area eg. neck of femur & intrathocanteric
48
What parameters should be screened before starting pharmacologic therapy?
1. Serum 25(OH)Vit D (should be ≥ 20-30ng/ml but < 50-100ng/ml) 2. Serum calcium
49
# True or False? Calcium and vit D supplementation should always be given even if patients are no deficient of them
True. Still give supplementation in normal levels
50
State the monitoring parameters for osteoporosis treatment
1. Serum Creatinine 2. Serum Calcium 3. Serum 25(OH) Vit D
51
State at least 4 nonpharmacological treatment for osteoporosis
1. Weight bearing, muscle stregthening & balance exercises 30min daily, 2-3x weekly (eg. Taichi, elastic band exercises, walking) 2. Limit alcohol intake (≤ 2U/day) 3. Reduce risks for fall - pt educatio on minimising fall risk eg. footwear, home modifications 4. Ensure adequate Ca intake- consider supplementation if dietary intake < 700mg/d 5. Maintain Vit D status - give 800IU/d cholecalciferol to those at risk of/has vit D insufficiency
52
How should patients be counselled when taking bisphosphonates with calcium supplements or calcium rich foods?
Space them 2H apart. Do not take them together
53